(Q45943683)

English

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

scientific article published in November 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

0 references

1 reference

based on heuristic

inferred from title

lupus erythematosus

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Jacqueline M McBride

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Jenny Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Alexander R Abbas

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Alyssa Morimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Jing Li

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Romeo Maciuca

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Michael Townsend

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Daniel J Wallace

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

William P Kennedy

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Jorn Drappa

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

publication date

1 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

64

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

3666-3676

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Review of recent genome-wide association scans in lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Genetic associations in type I interferon related pathways with autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Type I interferon correlates with serological and clinical manifestations of SLE

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Induction of clinical autoimmune disease by therapeutic interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

More powerful procedures for multiple significance testing

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Cytokines as therapeutic targets in SLE.

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Type I interferon in systemic lupus erythematosus and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

A critical function for type I interferons in cancer immunoediting

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Critical role for constitutive type I interferon signaling in the prevention of cellular transformation.

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Interferons, interferon-like cytokines, and their receptors

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Interferon-induced versus chemokine transcripts as lupus biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FART.34632

21 January 2018

Identifiers

10.1002/ART.34632

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/22833362

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45943683&oldid=2143927744"